Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULFINPYRAZONE vs COL-PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.
Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Chronic gouty arthritis,Hyperuricemia,Off-label: Prevention of gout flares during initiation of allopurinol
Treatment of gout flares,Prophylaxis of gout flares,Hyperuricemia associated with gout (probenecid component)
100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.
Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.
2-5 hours (terminal elimination half-life; prolonged in renal impairment to up to 10 hours)
Colchicine: terminal half-life 20-30 hours (up to 40-60 hours in renal impairment). Probenecid: 6-12 hours (dose-dependent, prolonged in renal disease).
Primarily hepatic via oxidation and conjugation; major metabolite is sulfinpyrazone sulfide.
Colchicine is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Probenecid is metabolized via glucuronidation and oxidation; it inhibits renal tubular secretion of many drugs and inhibits the metabolism of some drugs.
Renal: ~90% (50% unchanged, 50% as glucuronide and other metabolites); Biliary/fecal: ~10%
Colchicine: ~65% renal excretion as unchanged drug and metabolites; 10-20% biliary excretion. Probenecid: ~77-88% renal excretion (primarily as glucuronide conjugate); <15% biliary/fecal.
98-99% (primarily to albumin)
Colchicine: 30-50% bound to albumin. Probenecid: 85-95% bound to albumin.
0.15-0.25 L/kg (low Vd, consistent with high protein binding and limited tissue distribution)
Colchicine: Vd 2-4 L/kg (extensive tissue distribution, high affinity for tubulin). Probenecid: Vd 0.2-0.4 L/kg (limited extravascular distribution).
Oral: 80-90% (well absorbed; decreased with food)
Colchicine: Oral bioavailability ~50% (wide interindividual variability). Probenecid: Oral bioavailability ~100%.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Contraindicated in patients with Cr Cl < 50 m L/min. Use not recommended in severe renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Avoid use in Child-Pugh class B or C due to risk of colchicine accumulation. Use with caution in mild hepatic impairment, consider reducing dose.
Safety and efficacy not established; use not recommended.
Not recommended for use in children (safety and efficacy not established).
Start at lower end of dosing range (100-200 mg daily) and titrate cautiously due to increased risk of renal impairment and drug interactions.
Use with caution due to increased risk of renal impairment and accumulation. Start at lower doses (e.g., 1 tablet daily). Monitor renal function and for myelosuppression.
None.
None
Risk of acute gouty attacks during initial therapy,Uricosuric effect may lead to urolithiasis; maintain adequate hydration and urine alkalinization,Possible cross-allergenicity with sulfonamides,Monitor renal function and complete blood counts
Fatal overdoses have been reported with colchicine; do not exceed recommended dose.,Severe toxicity can occur with concomitant use of CYP3A4 or P-glycoprotein inhibitors.,Monitor renal function; dose adjustment required in renal impairment.,Hematologic toxicity (bone marrow suppression) with probenecid.,Uric acid stone formation; ensure adequate hydration and alkalinization of urine.,Drug interactions: colchicine with statins, macrolides, antifungals; probenecid with NSAIDs, penicillins, methotrexate.
Active peptic ulcer disease,Known hypersensitivity to sulfinpyrazone or sulfonamides,Severe hepatic or renal impairment
Hypersensitivity to colchicine or probenecid,Severe renal impairment (Cr Cl <10 m L/min),Hepatic impairment (colchicine),Blood dyscrasias (probenecid),Concurrent use of P-glycoprotein or CYP3A4 strong inhibitors (e.g., clarithromycin, ketoconazole) with colchicine
Avoid high-purine foods (e.g., organ meats, anchovies, sardines, beer) as they may reduce efficacy. Maintain adequate hydration; alcohol consumption should be minimized as it can increase uric acid levels.
Avoid or limit intake of high-purine foods (organ meats, anchovies, sardines, mussels, yeast extracts) as they may precipitate gout attacks. Alcohol (especially beer and spirits) increases urate production and decreases urate excretion, raising gout risk. Take with food to minimize gastrointestinal irritation.
Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of congenital malformations. Second and third trimester use may cause adverse fetal effects including premature closure of the ductus arteriosus, oligohydramnios, and renal dysfunction.
Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and third trimesters: Probenecid may cause fetal harm including nephrotoxicity and growth restriction. Colchicine may cause fetal toxicity at high doses.
Sulfinpyrazone is excreted into breast milk in small amounts. The M/P ratio is unknown. Due to the risk of serious adverse reactions in nursing infants, including the potential for kernicterus in jaundiced infants, use during breastfeeding is not recommended.
Colchicine: M/P ratio 0.93; small amounts excreted, monitor infant for gastrointestinal effects. Probenecid: Not recommended; M/P ratio unknown; avoid due to potential renal effects in infant.
No specific dose adjustments have been established. Due to increased renal blood flow and glomerular filtration rate during pregnancy, pharmacokinetics may be altered, but no dose recommendations are available. Sulfinpyrazone is not recommended for use in pregnancy.
Colchicine: Dose may need reduction due to increased volume of distribution and decreased clearance; monitor for toxicity. Probenecid: Dose adjustment may be needed due to increased renal clearance; monitor uric acid levels.
Sulfinpyrazone is a uricosuric agent used for chronic gout; avoid in acute gout attack. Monitor renal function and uric acid levels. Contraindicated in peptic ulcer disease due to GI irritation. May potentiate warfarin and sulfonylureas; adjust doses accordingly.
Colchicine and probenecid combination is used for gout prophylaxis and treatment. Monitor renal function closely; probenecid is contraindicated in Cr Cl <50 m L/min. Colchicine has a narrow therapeutic index and is contraindicated in patients with hepatic or renal impairment unless dose-adjusted. Avoid concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) which increase colchicine toxicity. Probenecid inhibits tubular secretion of many drugs (e.g., penicillins, methotrexate), increasing their levels.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce effectiveness.,Report any signs of bleeding, bruising, or abdominal pain immediately.,Do not stop abruptly; discuss with your doctor.
Take with food to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Report unusual bruising, bleeding, or signs of infection immediately.,Avoid alcohol as it increases serum urate levels and GI irritation.,Do not use this medication during a gout flare; wait until flare resolves.,Colchicine overdose can be fatal; seek emergency care if more than prescribed dose is taken.,Probenecid may cause false-positive urine glucose test with Clinitest.
"Tolvaptan, a vasopressin V2 receptor antagonist, may increase the serum concentration of sulfinpyrazone, a uricosuric agent, primarily through inhibition of OATP1B1/1B3 and possibly other hepatic uptake transporters. This interaction can lead to elevated sulfinpyrazone levels, raising the risk of adverse effects such as renal impairment or hypersensitivity reactions. Careful monitoring and dose adjustment of sulfinpyrazone are recommended when coadministered with tolvaptan."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, is a substrate of P-glycoprotein (P-gp) and may induce P-gp expression. Sulfinpyrazone, a uricosuric agent and P-gp inhibitor, can increase the bioavailability and systemic exposure of rifaximin by inhibiting its efflux transport. This interaction may lead to elevated rifaximin serum concentrations, potentially increasing the risk of systemic adverse effects such as Clostridioides difficile infection or hepatic impairment, though clinical data on this specific combination are limited."
"Colchicine may increase the serum concentration of sulfinpyrazone, a uricosuric agent, potentially enhancing its therapeutic effect and risk of toxicity. This interaction is likely mediated by colchicine's inhibition of hepatic cytochrome P450 enzymes and/or interference with biliary excretion of sulfinpyrazone. Clinically, this could lead to elevated sulfinpyrazone levels, increasing the risk of adverse effects such as gastrointestinal disturbances, hypersensitivity reactions, or renal impairment."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULFINPYRAZONE vs COL-PROBENECID, answered by our medical review team.
SULFINPYRAZONE is a Uricosuric that works by Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.. COL-PROBENECID is a Uricosuric that works by Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULFINPYRAZONE and COL-PROBENECID depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULFINPYRAZONE is: 100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.. The standard adult dose of COL-PROBENECID is: Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULFINPYRAZONE and COL-PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULFINPYRAZONE is classified as Category A/B. Sulfinpyrazone is contraindicated in pregnancy. Animal studies have shown teratogenic effects, and there are no adequate human studies. First trimester exposure may carry a risk of. COL-PROBENECID is classified as Category A/B. Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.